Seroatlas · Human Serome Atlas

RGS1

Regulator of G-protein signaling 1

Also known as: 1R20, BL34, IER1, IR20, RGS1_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q08116
Gene: RGS1
Ensembl: ENSG00000090104
Chromosome: 1
Canonical length: 209 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

This gene encodes a member of the regulator of G-protein signalling family. This protein is located on the cytosolic side of the plasma membrane and contains a conserved, 120 amino acid motif called the RGS domain. The protein attenuates the signalling activity of G-proteins by binding to activated, GTP-bound G alpha subunits and acting as a GTPase activating protein (GAP), increasing the rate of conversion of the GTP to GDP. This hydrolysis allows the G alpha subunits to bind G beta/gamma subunit heterodimers, forming inactive G-protein heterotrimers, thereby terminating the signal. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

209 residues, UniProt reviewed canonical sequence.

>Q08116|RGS1
     1  MRAAAISTPK LDKMPGMFFS ANPKELKGTT HSLLDDKMQK RRPKTFGMDM KAYLRSMIPH
    61  LESGMKSSKS KDVLSAAEVM QWSQSLEKLL ANQTGQNVFG SFLKSEFSEE NIEFWLACED
   121  YKKTESDLLP CKAEEIYKAF VHSDAAKQIN IDFRTRESTA KKIKAPTPTC FDEAQKVIYT
   181  LMEKDSYPRF LKSDIYLNLL NDLQANSLK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RGS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.44
Highest tissue expression: 415 nTPM

Expression across tissuesHPA

Tissue

spinal cord: 415 nTPM
choroid plexus: 165 nTPM
appendix: 161 nTPM
thymus: 144 nTPM
bone marrow: 143 nTPM
lymph node: 133 nTPM

Single-cell type

mast cells: 1,606 nCPM
macrophages: 790 nCPM
t-cells: 776 nCPM
cdc: 612 nCPM
pdcs: 549 nCPM
plasma cells: 440 nCPM

Immune cell

eosinophil: 26 nTPM
T-reg: 22 nTPM
memory CD4 T-cell: 5.1 nTPM
plasmacytoid DC: 4.9 nTPM
memory CD8 T-cell: 4.5 nTPM
naive CD8 T-cell: 3.7 nTPM

Brain region

white matter: 73 nTPM
choroid plexus: 69 nTPM
hypothalamus: 66 nTPM
medulla oblongata: 55 nTPM
spinal cord: 38 nTPM
thalamus: 32 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.51
gnomAD pLI: 0.78
gnomAD missense Z: 0.13
DepMap mean gene effect: 0.14
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RGS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RGS1 as an antibody target. Whether an autoantibody or antibody against RGS1 could matter depends on whether native RGS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RGS1 is annotated at the cell surface, where native RGS1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label RGS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...